Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors.

A library of pyrido[2,3-d]pyrimidines was designed as inhibitors of FGFR3 tyrosine kinase allowing possible interactions with an unexploited region of the ATP binding-site. This library was built-up with an efficient step of click-chemistry giving easy access to triazole-based compounds bearing a large panel of substituents. Among the 27 analogues synthesized, more than half exhibited 55-89% inhibition of in vitro FGFR3 kinase activity at 2 microM and one (19g) was able to inhibit auto-phosphorylation of mutant FGFR3-K650M in transfected HEK cells.

[1]  H. Kolb,et al.  The growing impact of click chemistry on drug discovery. , 2003, Drug discovery today.

[2]  J. Thiery,et al.  Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation , 2005, Molecular Cancer.

[3]  J. Kendrew,et al.  Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. , 1999, Journal of medicinal chemistry.

[4]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[5]  L. Gibbs,et al.  FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation. , 2007, Biochimica et biophysica acta.

[6]  A. Doherty,et al.  Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors , 1997 .

[7]  S. Hubbard,et al.  Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain , 1998, The EMBO journal.

[8]  François Radvanyi,et al.  Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. , 2005, Human molecular genetics.

[9]  F. Sasse,et al.  Synthesis of a Benzolactone Collection using Click Chemistry , 2007 .

[10]  I. Kaitila,et al.  Achondroplasia is defined by recurrent G380R mutations of FGFR3. , 1995, American journal of human genetics.

[11]  A. Doherty,et al.  Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. , 1997, Journal of medicinal chemistry.

[12]  A. Boutonnier,et al.  On the preparation of carbohydrate-protein conjugates using the traceless Staudinger ligation. , 2005, The Journal of organic chemistry.

[13]  W. Kuehl,et al.  Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. , 2001, Blood.

[14]  Giovanni Sorba,et al.  Click chemistry reactions in medicinal chemistry: Applications of the 1,3‐dipolar cycloaddition between azides and alkynes , 2008, Medicinal research reviews.

[15]  Zoran Radić,et al.  In situ click chemistry: enzyme inhibitors made to their own specifications. , 2004, Journal of the American Chemical Society.

[16]  M. Grøtli,et al.  Synthesis of 3-(1,2,3-triazol-1-yl)- and 3-(1,2,3-triazol-4-yl)-substituted pyrazolo[3,4-d]pyrimidin-4-amines via click chemistry: potential inhibitors of the Plasmodium falciparum PfPK7 protein kinase. , 2009, Organic & biomolecular chemistry.

[17]  M. Bernatowicz,et al.  Urethane protected derivatives of 1-guanylpyrazole for the mild and efficient preparation of guanidines , 1993 .

[18]  E. Jabs,et al.  Clinical spectrum of fibroblast growth factor receptor mutations , 1999, Human mutation.

[19]  M. G. Finn,et al.  Click Chemistry: Diverse Chemical Function from a Few Good Reactions. , 2001, Angewandte Chemie.

[20]  A. Hartmann,et al.  FGFR3 Mutations in Benign Skin Tumors , 2006, Cell Cycle.

[21]  J. Weissenbach,et al.  Clinical and genetic heterogeneity of hypochondroplasia. , 1996, Journal of medical genetics.

[22]  D. Iyengar,et al.  A New Novel and Practical One Pot Methodology for Conversion of Alcohols to Amines , 2000 .

[23]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[24]  M. Uttamchandani,et al.  "Click" synthesis of small molecule probes for activity-based fingerprinting of matrix metalloproteases. , 2006, Chemical communications.

[25]  Arnold Munnich,et al.  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia , 1994, Nature.

[26]  K. Fujimoto,et al.  C8-alkynyl- and alkylamino substituted 2′-deoxyguanosines: a universal linker for nucleic acids modification , 2008 .

[27]  P. L. Bergsagel,et al.  Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. , 2004, Blood.

[28]  Jean Weissenbach,et al.  A gene for achondroplasia–hypochondroplasia maps to chromosome 4p , 1994, Nature Genetics.

[29]  A. Munnich,et al.  Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). , 1996, Human molecular genetics.

[30]  M. Mohammadi,et al.  The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.

[31]  D. Chopin,et al.  Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. , 2006, Carcinogenesis.

[32]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[33]  D. Donoghue,et al.  FGFR activation in skeletal disorders: too much of a good thing. , 1997, Trends in genetics : TIG.

[34]  A. Munnich,et al.  Stop codon FGFR3 mutations in thanatophoric dwarfism type 1 , 1995, Nature Genetics.

[35]  A. Chase,et al.  Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074 , 2004, Leukemia.

[36]  P. Furet,et al.  Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. , 1999, Pharmacology & therapeutics.

[37]  T. H. van der Kwast,et al.  The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. , 2001, Cancer research.

[38]  W. Denny,et al.  Synthesis and Structure−Activity Relationships of Soluble 7-Substituted 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridin-2-amines and Related Ureas as Dual Inhibitors of the Fibroblast Growth Factor Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinases , 2005 .

[39]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[40]  I. Kaitila,et al.  A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia , 1995, Nature Genetics.

[41]  T. Prangé,et al.  Synthesis of C‐Nucleosidic ATP Mimics as Potential FGFR3 Inhibitors , 2006 .

[42]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[43]  Y. Merrer,et al.  Efficient access to ATP mimics, potential FGF receptor tyrosine kinase inhibitors , 2002 .

[44]  S. Serrano,et al.  FGFR3 mutations in prostate cancer: association with low-grade tumors , 2009, Modern Pathology.

[45]  S. Hubbard,et al.  Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. , 1997, Science.

[46]  M. Knowles,et al.  Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma , 2001, Oncogene.

[47]  J. Galzi,et al.  Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. , 2004, Journal of medicinal chemistry.